Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Why Pharma Doesn't Always Keep Phase IV Promises In India

Executive Summary

Are drug firms being lax when it comes to Phase IV studies in markets like India or are certain arbitrarily determined regulatory requirements largely to blame? Scrip delves into the issue.


Related Content

Roche To Set Right Avastin Post-Marketing Surveillance Delay In India
AstraZeneca's Imfinzi, Lynparza On Track To India Debut
Patient Safety First But India’s ‘Interim Compensation’ Trial Rule May Spook Sponsors
Indian Panel Nudges Eisai Towards Phase IV Compliance For Halaven
Interview: Real World Evidence’s Commercial Facet
India’s Expanded Trial Waiver Proposal Sets R&D Site Inspection Clause


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts